checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


No label-required laboratory prescreening or ongoing monitoring during treatment1

 

MARKED LABORATORY ABNORMALITIES WERE GENERALLY INFREQUENT AND TRANSIENT ACROSS EXPOSURE PERIODS2,a

otezla selected marked abnormalities in laboratory parameters
a

Represents the number of patients with ≥1 occurrence of the abnormality at any time point/number of patients with ≥1
post-baseline value.

b

Includes all patients who received apremilast during the exposure interval relative to the start of apremilast administration.

Discontinuation rates were generally low2,3

  • Discontinuation of treatment due to any adverse reaction was 4.6% for patients taking OTEZLA vs 1.2% for placebo by week 16
  • Discontinuation due to adverse reactions occurred at a lower rate over time: 1.6% in year 3, 2.4% in year 2, and 7.5% in year 1

ULN, upper limit of normal.

References: 1. OTEZLA Summary of Product Characteristics. Stockley Park, Uxbridge, UK: Celgene Europe, Ltd; 2016. 2. Mease PJ, Gladman DD, Gomex-Reino JJ, et al. Long-term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK. 3. Data on file, Celgene Corporation.


Select an e-mail client to share

close x